Tudor Investment Corp ET AL Acquires Shares of 34,891 LifeMD, Inc. (NASDAQ:LFMD)

Tudor Investment Corp ET AL bought a new position in LifeMD, Inc. (NASDAQ:LFMD - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 34,891 shares of the company's stock, valued at approximately $173,000. Tudor Investment Corp ET AL owned about 0.08% of LifeMD at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Oxford Asset Management LLP purchased a new position in shares of LifeMD during the 4th quarter worth $52,000. Price T Rowe Associates Inc. MD lifted its stake in shares of LifeMD by 26.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,012 shares of the company's stock valued at $70,000 after buying an additional 2,895 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of LifeMD by 522.9% during the 4th quarter. Marshall Wace LLP now owns 371,473 shares of the company's stock valued at $1,839,000 after buying an additional 311,841 shares in the last quarter. Jump Financial LLC lifted its stake in shares of LifeMD by 63.8% during the 4th quarter. Jump Financial LLC now owns 99,379 shares of the company's stock valued at $492,000 after buying an additional 38,722 shares in the last quarter. Finally, Mariner LLC purchased a new position in shares of LifeMD during the 4th quarter valued at $67,000. Hedge funds and other institutional investors own 35.52% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on LFMD shares. HC Wainwright restated a "buy" rating and set a $14.00 target price on shares of LifeMD in a research note on Wednesday, April 30th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $15.00 price target on shares of LifeMD in a report on Tuesday, March 11th. Finally, B. Riley upgraded shares of LifeMD to a "strong-buy" rating in a report on Tuesday, March 11th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $11.00.

Insider Transactions at LifeMD

In related news, CMO Jessica Friedeman sold 30,000 shares of the company's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $5.66, for a total transaction of $169,800.00. Following the transaction, the chief marketing officer now directly owns 170,000 shares in the company, valued at approximately $962,200. This represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Justin Schreiber sold 21,995 shares of the company's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $7.53, for a total transaction of $165,622.35. Following the transaction, the chief executive officer now owns 2,553,726 shares in the company, valued at $19,229,556.78. The trade was a 0.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 101,995 shares of company stock worth $724,422 in the last three months. Insiders own 15.97% of the company's stock.

LifeMD Stock Up 10.6%

NASDAQ LFMD traded up $1.02 on Friday, reaching $10.69. The company had a trading volume of 1,213,931 shares, compared to its average volume of 1,428,542. The stock has a market capitalization of $485.93 million, a PE ratio of -16.67 and a beta of 2.22. The firm's 50 day moving average price is $6.21 and its 200 day moving average price is $5.81. LifeMD, Inc. has a 12 month low of $3.99 and a 12 month high of $10.67.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.05. The business had revenue of $65.70 million during the quarter, compared to the consensus estimate of $62.47 million. On average, research analysts expect that LifeMD, Inc. will post -0.56 EPS for the current year.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.